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Abstract
Salmonella enterica serovar Typhi expresses a capsule of Vi polysaccharide, while most
Salmonella serovars, including S. Enteritidis and S. Typhimurium, do not. Both S. Typhi and
S. Enteritidis express the lipopolysaccharide O:9 antigen, yet there is little evidence of
cross-protection from anti-O:9 antibodies. Vaccines based on Vi polysaccharide have effi-
cacy against typhoid fever, indicating that antibodies against Vi confer protection. Here we
investigate the role of Vi capsule and antibodies against Vi and O:9 in antibody-dependent
complement- and phagocyte-mediated killing of Salmonella. Using isogenic Vi-expressing
and non-Vi-expressing derivatives of S. Typhi and S. Typhimurium, we show that S. Typhi is
inherently more sensitive to serum and blood than S. Typhimurium. Vi expression confers
increased resistance to both complement- and phagocyte-mediated modalities of antibody-
dependent killing in human blood. The Vi capsule is associated with reduced C3 and C5b-9
deposition, and decreased overall antibody binding to S. Typhi. However, purified human
anti-Vi antibodies in the presence of complement are able to kill Vi-expressing Salmonella,
while killing by anti-O:9 antibodies is inversely related to Vi expression. Human serum
depleted of antibodies to antigens other than Vi retains the ability to kill Vi-expressing bacte-
ria. Our findings support a protective role for Vi capsule in preventing complement and
phagocyte killing of Salmonella that can be overcome by specific anti-Vi antibodies, but only
to a limited extent by anti-O:9 antibodies.
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Introduction
Salmonella enterica serovar Typhi (S. Typhi) is the causative agent of the systemic disease
typhoid fever. Humans are the only known natural hosts of S. Typhi [1] with an estimated 12
to 22 million cases of typhoid fever per annum resulting in between 129,000 and 217,000
deaths [2, 3].
The majority of clinical S. Typhi isolates express a polysaccharide capsule (Vi CPS) known
as Vi (Vi+ S. Typhi) [4] which is associated with virulence [5, 6]. Vi exhibits immunomodula-
tory activities. For example, Vi expression on Salmonella can reduce the inflammatory
response in intestinal epithelial cells [7] and throughout systemic infection. Such signatures
include reduced levels of growth related oncogene α (GROα) and IL-17, and reduced fluid
influx and neutrophil recruitment in the Salmonella bovine ileal loop model [8]. Vi expression
can thus facilitate a stealth mode of pathogenesis promoting systemic spread and limiting the
clinical signatures of gastroenteritis [9]. Vi expression can also reduce the deposition of C3 on
the surface of S. Typhi and provide protection against non-specific antibody killing [6, 10].
In addition to Vi capsule, S. Typhi also expresses the O:9 antigen of lipopolysaccharide, a
feature shared with other clinically important Salmonella serovars, particularly S. Enteritidis.
Antibodies to O:9 have bactericidal potential, reducing bactericidal loads post challenge with S.
Enteritidis, and consequently O:9-based conjugate vaccines are in development to prevent
invasive nontyphoidal Salmonella disease in Africa [11]. Characterizing the action of anti-O:9
antibodies against S. Typhi, and the effect of Vi expression on activity of these antibodies
could help understand what potential O:9 conjugate vaccines might have in protection against
typhoid fever.
Three licensed vaccine types have been used to prevent typhoid fever [12]. Inactivated
whole cell vaccines have some efficacy, but these are associated with high reactogenicity. Ty21a
is a live attenuated oral vaccine derived from S. Typhi Ty2, that does not express a Vi polysac-
charide capsule due to mutations within the Vi locus (viaB). While the Ty21a typhoid vaccine
lacks Vi capsule, it is unclear whether the protection afforded by this vaccine is mediated by
anti-O:9 antibodies.
A third type of vaccine is based on Vi CPS administered intramuscularly. Ty21a and Vi CPS
have similar limited cumulative efficacies of approximately 55% at 3 years post-vaccination,
despite being based on different antigens and formulations. These vaccines are not recom-
mended for use in children under two years of age [12]. Both Ty21a and Vi CPS vaccines
require refrigeration and neither has been implemented in national public health programs.
An effective vaccine that can be used in infants remains a public health priority, and new Vi
glycoconjugate vaccines are currently in development [12, 13].
This study uses both wild-type S. Typhi and pairs of isogenic Vi+ and Vi- derivatives of S.
Typhi and S. Typhimurium [14] to investigate the relationship between the Vi capsule and
antibody-dependent immunity to Salmonella, in particular the role of human anti-Vi and anti-
O:9 antibodies.
Results
Vi capsule increases resistance of S. Typhi and S. Typhimurium to
antibody-dependent complement-mediated killing by human serum
We performed bactericidal assays using sera from ten healthy adult donors (S1 Table and S1
Fig) and isogenic Vi+ and Vi- isolates of S. Typhi and S. Typhimurium. Vi expression by both
S. Typhimurium (Fig 1A) and S. Typhi (Fig 1B) enhanced bacterial survival indicating that the
protective effect of Vi against complement-mediated killing is not restricted to the serovar
Salmonella Typhi Antibody Killing
PLOS ONE | DOI:10.1371/journal.pone.0145945 January 7, 2016 2 / 17
manuscript. The specific role of this author is
articulated in the ‘author contributions’ section.
Competing Interests: The authors have the
following interests. Calman A. MacLennan is the
recipient of a clinical research fellowship from
GlaxoSmithKline. Francesca Micoli is an employee of
the Sclavo Behring Vaccines Institute for Global
Health. Calman A. MacLennan was an employee of
the Novartis Vaccines Institute for Global Health in
the past. There are no patents, products in
development or marketed products to declare. This
does not alter the authors' adherence to all the PLOS
ONE policies on sharing data and materials, as
detailed online in the guide for authors.
Typhi. Vi+ C5.507 S. Typhimurium was more resistant to killing compared to the isogenic Vi-
strain, SGB1 (p<0.0001, all time points), and Vi+ S. Typhi BRD948 was more resistant to kill-
ing at 45 and 90 minutes compared with Vi- S. Typhi BRD948 (p<0.0001, both time points).
Both Vi+ and Vi- S. Typhi BRD948 derivatives underwent a 3 log10 kill by 3 hours and were
inherently more sensitive to complement-mediated killing than their Vi+ and Vi- S. Typhimur-
ium counterparts.
Vi capsule increases the resistance of S. Typhi and S. Typhimurium to
antibody-dependent phagocyte-mediated killing
Blood cell killing assays were performed using the isogenic Salmonella isolates opsonized with
heat-inactivated serum and fresh C6-deficient serum. C6-deficient serum was used as the
source of complement, because it permits opsonization with C3b, but does not result in mem-
brane attack complex formation. Vi+ and Vi- S. Typhi BRD948 were both more inherently sus-
ceptible to phagocyte-mediated killing than Vi+ and Vi- S. Typhimurium. Vi+ S. Typhimurium
C5.507 was more resistant to blood cell killing than Vi- S. Typhimurium SGB1 after 90 and
180 minutes (p = 0.042 and 0.047 respectively) (Fig 1C). Vi+ S. Typhi BRD948 was markedly
Fig 1. Vi increases serum resistance of Salmonella and reduces killing of Salmonella by peripheral blood phagocytes. Killing of isogenic Vi-
expressing and non-expressing S. Typhimurium (A) and S. Typhi (B) strains by ten individual adult sera characterized for anti-Salmonella antibody content in
S1 Fig. For blood cell killing, isogenic Vi-expressing and non-expressing S. Typhimurium (C) and S. Typhi (D) were opsonized with antibodies from ten adult
sera and C6-deficient serum then added to washed peripheral blood cells. Killing of Salmonella strains expressing (dashed lines) or not expressing (dotted
lines) Vi capsule was recorded at 45, 90 and 180 minutes. C6-deficient serum was used as the source of complement, because it permits opsonization with
C3b, but does not result in membrane attack complex formation. Solid lines in A and B are Vi+ and Vi- bacteria incubated with heat-inactivated sera (HiS).
Solid lines in C and D represent Salmonella incubated with PBS and added to blood cells, or opsonized with serum and added to RPMI. Lines represent
mean values using sera from ten adults in triplicate experiments. Error bars represent SEM.
doi:10.1371/journal.pone.0145945.g001
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more resistant to phagocyte killing than Vi- S. Typhi BRD948 at 45 and 90 minutes (p<0.01)
(Fig 1D).
Vi expression reduces damage to Salmonella following exposure to
serum
Damage to Vi-expressing and non-expressing Salmonella following exposure to human serum
was explored using serum from donor 1, because it contains IgG antibodies to Vi, O:9 and
O:4,5, and was visualized by transmission electron microscopy (TEM). For all isolates, expo-
sure to PBS for 10 minutes had no obvious effect on cellular integrity (Fig 2A–2D). Vi+ S.
Typhimurium C5.507 exhibited minimal signs of cellular damage following serum exposure
for 10 minutes (Fig 2E), but accumulated a distinct, irregular outer layer on the cell surface,
consistent with complement deposition. Both Vi- S. Typhimurium C5.507 and Vi+ S. Typhi
BRD948 exhibited similar signs of damage, including enlargement of the periplasmic space
with cytoplasmic contraction (Fig 2F and 2G respectively) while Vi- S. Typhi cells showed
extensive damage (Fig 2H). After scoring multiple images (n = 3), more Vi- S. Typhimurium
and Vi- S. Typhi cells displayed indicators of damage compared to their Vi-expressing counter-
parts (p = 0.008 and 0.004 respectively) (S2 Fig). Hence, the expression of a Vi capsule is associ-
ated with reduced damage after short-term exposure to serum, even in the presence of anti-Vi
antibodies.
Vi capsule reduces antibody binding and complement deposition in the
absence of Vi-specific IgG
Wemeasured total IgG and IgM binding, and C3 and MAC deposition on the isogenic Vi+ and
Vi- Salmonella isolates, following independent incubation with the ten human sera in S1 Table.
When incubated with the four sera containing anti-Vi IgG, levels of total IgG binding to both
Vi+ S. Typhi and Vi+ S. Typhimurium were not significantly different compared with their iso-
genic Vi- partner strains (Fig 3A). When incubated with the six sera lacking Vi-specific IgG,
there was an increase in median total IgG binding to Vi- SGB1 compared with Vi+ C5.507 S.
Typhimurium, although this did not reach statistical significance with the number of samples
involved. In the absence of anti-Vi IgG, significantly less IgG bound to Vi+ S. Typhi BRD948
compared with the isogenic Vi- counterpart (p = 0.026) (Fig 3B).
With sera containing anti-Vi IgG, no significant difference in C3 deposition was detected
between Vi+ S. Typhimurium C5.507 and Vi- S. Typhimurium SGB1, while significantly lower
C3 deposition occurred on Vi+ S. Typhi compared with its Vi- equivalent (p = 0.029) (Fig 3C).
In the absence of anti-Vi IgG, expression of Vi was associated with significantly reduced C3
deposition on both Vi+ S. Typhimurium C5.507 and Vi+ S. Typhi BRD948 compared with the
isogenic Vi- equivalents (p = 0.002 and 0.004 respectively) (Fig 3D). No differences in levels of
MAC deposition were detected between Vi-expressing and non-expressing Salmonella when
anti-Vi IgG was present in the sera, although a trend for increased MAC deposition was
observed with Vi- S. Typhi (Fig 3E). With sera lacking anti-Vi IgG, expression of Vi was associ-
ated with significantly reduced MAC deposition on both S. Typhimurium C5.507 and S. Typhi
BRD948 (p = 0.026 and 0.009) (Fig 3F). Binding of total IgM from the ten sera was significantly
lower for Vi+ S. Typhi BRD948 compared with the isogenic Vi- counterpart (p = 0.014), but
not for Vi+ S. Typhimurium C5.507 compared with the Vi- equivalent (Fig 3G). All ten sera
contained IgM anti-Vi antibodies. Incubation with PBS followed by each secondary antibody
was performed as a negative control (S3 Fig).
Salmonella Typhi Antibody Killing
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Depletion of serum anti-Vi antibodies reduces killing of Vi-expressing
Salmonella
To investigate the functional role of anti-Vi antibodies in killing of Salmonella, donor 1 serum
was used as it contains IgG antibodies to Vi, O:9 and O:4,5. This was adsorbed by incubation
with each of the two pairs of isogenic Vi+ and Vi- S. Typhimurium and S. Typhi isolates, lead-
ing to selective depletion of antibodies to Vi, O:9 and O:4,5 (S4 Fig). With the exception of Vi-
S. Typhi, which is sensitive to killing by complement in the absence of specific antibodies,
adsorbed serum was unable to kill the isolate used for adsorption (homologous isolate) (Fig 4).
Adsorbed sera were able to kill all other isolates (heterologous isolates), whether heterologous
by serovar or for Vi expression. Hence, sera adsorbed with Vi- Salmonella could still kill the iso-
genic Vi+ Salmonella strain of the same serovar (p = 0.005 and<0.0001 for S. Typhimurium
and S. Typhi respectively) (Fig 4A and 4B). This is consistent with complement-mediated kill-
ing secondary to binding of anti-Vi antibodies. Similarly, sera adsorbed with the Vi+ Salmo-
nella could kill the Vi+ Salmonella derivative of the heterologous serovar (p = 0.018 and 0.0003
for S. Typhimurium and S. Typhi respectively). This is consistent with killing of Vi+ Salmonella
by non-Vi antibodies such as anti-O:9 and anti-O:4,5 and suggests that the Vi capsule does not
fully prevent access of non-Vi antibodies to their targets.
Altered osmolarity reduces Vi expression, enhancing anti-O:9 antibody
binding to wild-type S. Typhi
Vi expression on Salmonella is influenced by osmolarity, surface expression being down-regu-
lated as osmolarity increases [14, 15]. We affinity purified anti-Vi and anti-O:9 antibodies
from a pool of sera from three healthy adults who had been vaccinated with Vi CPS (S5 Fig)
and used these to examine the effect of altered Vi expression on antibody binding. Five
Fig 2. Vi capsule protects against cell damage following serum exposure.Cellular integrity of and damage to Salmonellawas assessed by transmission
electron microscopy (TEM) after exposure to PBS or human sera. TEM images of isogenic (A and E) Vi+ S. Typhimurium, (B and F) Vi- S. Typhimurium, (C
and G) Vi+ S. Typhi and (D and H) Vi- S. Typhi after incubation with either PBS (A–D respectively) or with undiluted human serum from Donor 1 (E–H
respectively) for ten minutes. Representative images shown.
doi:10.1371/journal.pone.0145945.g002
Salmonella Typhi Antibody Killing
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different wild-type S. Typhi isolates were cultured at 9, 85 and 500 mMNaCl in order to modu-
late expression of the Vi capsule. Anti-Vi antibody binding to S. Typhi was highest when Sal-
monella was cultured at 9mMNaCl and minimal when cultured at 500 mMNaCl (Fig 5A),
consistent with increased Vi expression at low osmolarity and the converse at high osmolarity.
Anti-O:9 antibody binding to S. Typhi was highest at 500 mMNaCl, where Vi expression is
minimal, most likely due to enhanced access to target antigen, unimpeded by Vi capsule. Anti-
O:9 binding in 85 and 9 mMNaCl, where Vi expression is increased, was significantly lower
Fig 3. Vi expression decreases antibody and complement binding to Salmonella in the absence of
specific antibodies. Levels of (A and B) IgG, (C and D) C3 and (E and F) C5b-9 MAC on Vi-expressing and
non-expressing Salmonella Typhimurium (STM) and S. Typhi (STY) after incubation with sera containing anti-
Vi IgG (A, C and E) or lacking anti-Vi IgG (B, D and F) were measured by flow cytometry. Levels of IgM
binding to Vi+/- Salmonella for all ten sera were also assessed (G). All sera contained IgM anti-Vi antibodies.
Bars represent mean +/- SEM
doi:10.1371/journal.pone.0145945.g003
Salmonella Typhi Antibody Killing
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Fig 4. Sera depleted of Salmonella-specific antibodies effect variable killing of different Salmonella strains. Killing of Vi+ S. Typhimurium (STM) (A)
and S. Typhi (STY) (B) and Vi- S. Typhimurium (C) and S. Typhi (D) by donor 1 serum adsorbed of antibodies with Vi+ and Vi- S. Typhimurium and S. Typhi or
unadsorbed serum. Dashed lines represent killing of Salmonella by sera adsorbed using the homologous Salmonella strain. Dotted lines represent killing by
unadsorbed serum. Experiments were performed in triplicate and error bars represent SEM. Initial concentration of bacteria in each assay was 106 CFU/ml.
doi:10.1371/journal.pone.0145945.g004
Fig 5. Media osmolarity affects the binding of human anti-Vi and anti-O:9 antibodies to wild-type S. Typhi. Five wild-type S. Typhi isolates, one from
each geographical site to ensure the greatest geographical variation among strains studied, were cultured in LB broth containing 9, 85 or 500mMNaCl and
incubated with either purified human anti-Vi (A) or anti-O:9 (B) antibodies or PBS. Levels of antibody binding to S. Typhi were assessed by flow cytometry.
Values are mean of three separate experiments. Bars represent mean +/- SEM.
doi:10.1371/journal.pone.0145945.g005
Salmonella Typhi Antibody Killing
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(p = 0.008 for both), but still detectable (p<0.007 for both compared with negative control)
(Fig 5B) Thus, there was a negative correlation between anti-Vi and anti-O:9 antibody binding
to S. Typhi isolates cultured at 9, 85 and 500mMNaCl (S6 Fig) (r = -0.62, p = 0.016). These
findings are consistent with Vi capsule limiting access of anti-O:9 antibodies.
Altered osmolarity and Vi expression modulates killing by anti-Vi and
anti-O:9 antibodies
We assessed the bactericidal and opsonic potential of purified human anti-Vi and anti-O:9
antibodies against 14 wild-type S. Typhi isolates cultured in ordinary LB broth (85mMNaCl),
and five (one from each geographical site to ensure the greatest geographical variation among
strains studied, and the same five as used in Fig 5) cultured in LB broth at 9 and 500 mMNaCl
(Fig 6). Anti-Vi and anti-O:9 antibodies were bactericidal against S. Typhi. Anti-Vi antibodies
killed S. Typhi with normal (Fig 6B) or enhanced (Fig 6A) Vi expression more effectively than
anti-O:9 antibodies. With minimal Vi expression, the effect was reversed, with anti-O:9 anti-
bodies effecting a 3 log10 kill of all five S. Typhi isolates and reduced bactericidal activity of
anti-Vi antibodies (Fig 6C). Anti-O:9 antibodies poorly facilitated opsonophagocytic killing of
S. Typhi expressing normal or elevated amounts of Vi, being unable to kill all but two S. Typhi
strains. In contrast, S. Typhi with normal or elevated Vi and opsonized with anti-Vi antibodies
were effectively killed by blood phagocytes (Fig 6D and 6E). The opsonic activity of anti-O:9
Fig 6. Bactericidal and opsonic activity of anti-Vi and anti-O:9 antibodies against S. Typhi depends onmedium osmolarity. The bactericidal (A–C)
and opsonic (D–F) activity of purified human anti-Vi (red lines) and anti-O:9 (blue lines) antibodies supplemented with human complement was tested against
wild-type S. Typhi. S. Typhi isolates were cultured in LB Broth containing 9 (high Vi expression, A and D), 85 (B and E) or 500mM (low Vi expression, C and
F) NaCl. Isolates tested at 9mM or 500mMNaCl concentrations were the same and included in the 14 isolates tested at 85mMNaCl. They were selected
from each geographical site to ensure the greatest geographical variation among strains studied. Each line represents an individual S. Typhi isolate. Data
represent mean of three separate experiments +/- SEM.
doi:10.1371/journal.pone.0145945.g006
Salmonella Typhi Antibody Killing
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antibodies against S. Typhi was greater than that of anti-Vi antibodies when Salmonella had
reduced Vi expression (Fig 6F).
MAC deposition in the presence of anti-Vi antibodies, but not anti-O:9
antibodies, correlates with killing of S. Typhi in the serum bactericidal
assay
We assessed MAC deposition in the presence of purified anti-Vi and anti-O:9 antibodies on S.
Typhi expressing different amounts of Vi through changes in osmolarity. For anti-Vi antibod-
ies, MAC deposition was highest when conditions favored Vi expression on Salmonella, and
decreased as Vi expression was reduced (Fig 7A). Somewhat surprisingly, there were similar
levels of MAC deposition with anti-O:9 antibodies irrespective of the level of expression of Vi
(Fig 7B). In the presence of anti-Vi antibodies, MAC deposition correlated with killing (Spear-
man’s r = -0.8, p = 0.0004) (Fig 7C). However, there was no correlation between levels of MAC
deposition with anti-O:9 antibodies and killing of S. Typhi (Fig 7D). This suggests that MAC
Fig 7. MAC deposition in the presence of anti-Vi, but not anti-O:9 antibodies, is associated with bactericidal activity. Levels of C5b-9 MAC deposition
on the surface of five wild-type S. Typhi isolates cultured at 9, 85 and 500mMNaCl in the presence of purified human anti-Vi antibodies (A) or anti-O:9
antibodies (B) were measured by flow cytometry. For each of the five isolates at each concentration of sodium chloride, killing in the serum bactericidal assay
was plotted against the level of MAC deposition for anti-Vi antibodies (C) or anti-O:9 antibodies (D). Data are mean of three separate experiments. Bars
represent mean +/- SEM.
doi:10.1371/journal.pone.0145945.g007
Salmonella Typhi Antibody Killing
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deposition secondary to binding of O:9 antibodies is not effective at killing in the presence of
high levels of Vi antigen.
Discussion
We have examined the relationship between Vi polysaccharide expression in Salmonella and
sensitivity to killing by antibody, complement and blood phagocytes from healthy adults. We
demonstrate that antibodies to Vi can be bactericidal and opsonic and kill Vi-expressing S.
Typhi and S. Typhimurium. The level of killing correlated with Vi expression.
Our findings indicate an inherent difference in resistance to complement-mediated killing
between Typhi and Typhimurium serovars. Vi- S. Typhi was considerably more sensitive to
complement-mediated killing than the equivalent S. Typhimurium and can be killed by com-
plement alone in the absence of specific antibodies. This may explain why the majority of S.
Typhi that cause disease express a Vi capsule. Our observation that Vi expression by Salmo-
nella is associated with an increase in serum resistance is in agreement with previous findings
[6, 10], but contrasts with work by Bravo et al [16]. This may be a consequence of differing
methods with Bravo et al limiting their serum bactericidal assay to 20 minutes with a maxi-
mum serum concentration of 20%.
S. Typhimurium was compared with S. Typhi, because S. Typhimurium is the commonest
serovar responsible for invasive nontyphoidal Salmonella disease, while S. Typhi is the most
common serovar responsible for enteric fever [12, 17]. Therefore, these are the two Salmonella
serovars most in need of a vaccine and so the serovars for which it is most important to under-
stand the basis of protective immunity in man. Similar findings to those obtained with S.
Typhimurium would be expected with S. Enteritidis, since both serovars show a comparable
level of resistance to antibody-mediated killing in serum [18].
As previously shown with O-antigen-expressing invasive clinical S. Typhimurium isolates
from Africa [19], Vi- S. Typhimurium is not susceptible to killing by complement alone and
requires more complement than other Salmonella serovars to be killed [20]. Killing of Vi- S.
Typhimurium by undiluted, control adult human serum is more gradual than for Vi- S. Typhi.
Unlike the Vi- equivalent, Vi+ S. Typhi BRD948 demonstrated similar resistance to killing by
healthy human adult serum as Vi- S. Typhimurium SGB1 with both these strains incurring
similar levels of structural damage following exposure to serum (Fig 2). If, as we have previ-
ously suggested [21], such a level of serum resistance is optimal for Salmonella to successfully
survive as a pathogen in man, this could explain in part why the inherently more complement-
susceptible S. Typhi have a Vi capsule, while S. Typhimurium do not.
We found a significant reduction in MAC deposition on the Vi+ S. Typhimurium and
Typhi compared to their respective isogenic Vi- counterparts when exposed to sera lacking
anti-Vi IgG. A reduction in C3 deposition, under the same conditions, is in agreement with
previous work [6, 10]. Total IgG and IgM binding to Vi-expressing S. Typhi, was significantly
lower than to Vi- S. Typhi, particularly when sera lacked anti-Vi IgG. Differences in the level of
Vi expression between Vi+ S. Typhi and S. Typhimurium, with relatively lower Vi expression
by the S. Typhimurium strain, may partly explain why Vi expression was not associated with
significant reductions in IgG and IgM binding to S. Typhimurium. However, inactivation of
fepE is common in S. Typhi and results in the loss of very-long O-antigen chains [22], reducing
the opportunity for binding of anti-O-antigen antibodies, particularly in the presence of a Vi
capsule.
These findings are consistent with the concept that Vi expression impedes complement-
mediated killing, either by 1. restricting binding of antibodies to the Salmonella surface, 2.
restricting binding of antibodies to O-antigen, 3. directly reducing the deposition of
Salmonella Typhi Antibody Killing
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complement factors, 4. diverting complement deposition to sites where it is not bactericidal or
5. a combination of these mechanisms. A reduction in complement deposition resulting from
the modification of surface structures has been shown to result in increased resistance to killing
in other bacteria including E. coli K1 [23] and N.meningitidis [24].
Purifying human anti-Vi and anti-O:9 antibodies allowed us to explore the role of each type
of antibody in killing of S. Typhi in greater detail. By altering the medium osmolarity, we were
able to vary expression of Vi and investigate how this affected antibody-mediated killing.
Human anti-Vi antibodies effected bactericidal and opsonic activity against wild-type S. Typhi
under conditions of Vi capsule expression. The bactericidal, but not the opsonophagocytic kill-
ing activity of anti-Vi antibodies was slightly reduced at 9mM NaCl, where Vi expression is
greatest, compared to 85mMNaCl. This is consistent with the Vi capsule having intrinsic prop-
erties which augment resistance to killing by the membrane attack complex, a structure which
is not involved in opsonophagocytic killing, despite the presence of capsule specific antibodies.
Under the same conditions, anti-O:9 antibodies exerted some bactericidal activity against S.
Typhi, but were poorly able to facilitate opsonophagocytic killing. With loss of Vi capsule
expression at 500mMNaCl, binding, bactericidal and opsonic activity of anti-O:9 antibodies
was greatly enhanced.
S. Enteritidis is one of the most prevalent serovars of NTS globally [25], thus circulating
anti-O:9 antibodies are likely to be present in a large proportion of the population. All ten
serum donors had detectable anti-O:9 IgG and IgM. However, it has not been known whether
the presence of anti-O:9 antibodies confers protection against S. Typhi. Our findings suggest
that, while anti-O:9 antibodies may effect some complement-mediated bactericidal activity
against S. Typhi, they are unlikely to contribute to phagocyte-mediated killing in the presence
of Vi capsule. Since ViLOW S. Typhi are highly susceptible to both bactericidal and opsonic
killing by anti-O:9 antibodies, it appears that Vi mitigates the action of anti-O:9 antibodies,
thereby providing another rationale for why the majority of clinical S. Typhi isolates express a
Vi capsule [4].
Anti-O:9 antibodies were still able to bind to S. Typhi under conditions of Vi expression,
resulting in MAC deposition. However, while MAC deposition in the presence of anti-Vi anti-
bodies correlated with killing, this was not the case with MAC deposition secondary to anti-
O:9 binding. This suggests that Vi capsule does not fully obstruct access to O-antigen allowing
both anti-O:9 antibodies to bind and MAC deposition to occur, but without killing. Such dif-
ferential killing by MAC suggests that the location of MAC deposition on the bacterium is a
key determinant for whether S. Typhi are killed.
An important implication of these findings relates to the variable expression of Vi [26] and
the frequency of anti-O:9 antibodies in humans. Antibodies to nontyphoidal Salmonella sero-
vars, such as O:9 expressed by S. Enteritidis, are acquired rapidly in the first years of life in
regions such as sub-Saharan Africa [19, 27] and are likely present in most adults in all popula-
tions later in life. Since Vi antigen is expressed under conditions of low osmolarity, such as
would be expected within the bloodstream, it can help protect against killing by these widely
prevalent anti-O:9 antibodies aiding the establishment of infection with S. Typhi. Similarly, it
has previously been shown that the Vi capsule, when expressed by S. Typhimurium, reduces,
but does not fully remove, protection mediated by antibodies to Salmonella porins [28].
In conclusion, these results support the concept that expression of the Vi capsule increases
resistance to O:9 and other non-Vi antibodies, complement killing by MAC and opsonization
for killing by phagocytes. Modulation of Vi expression has the potential to vary sensitivity dur-
ing the infection cycle to O:9-specific antibodies induced through exposure to ubiquitous S.
Enteritidis strains. This may facilitate the establishment of initial systemic infection by S. Typhi
and subsequent chronic carrier state. The study suggests the existence of a dichotomy whereby
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Vi expression prolongs S. Typhi survival in a naive host through enhanced complement resis-
tance, but in the presence of anti-Vi antibodies, protection is overcome. These findings inform
the development of vaccines against typhoid fever and other invasive forms of Salmonella
disease.
Materials and Methods
Bacteria and culture conditions
S. Typhimurium were the Vi-negative isolate SGB1 and the Vi-positive isolate C5.507, which
harbors the S. Typhi viaB locus and expresses the Vi polysaccharide capsule [14]. The Vi-posi-
tive S. Typhi aromutant BRD948 (S. Typhi Ty2 aroC- aroD- htrA-) and an otherwise isogenic
Vi-negative tviBmutant derivative were used throughout. Other wild-type S. Typhi isolates
were from Central Africa, Nepal and Indonesia, and Moshi and Muheza in Tanzania. Bacteria
were cultured on LB agar plates or in LB broth and, in the case of aromutants, LB broth and
agar were supplemented with tyrosine, tryptophan and phenylalanine at a final concentration
of 40 μg/L and para-aminobenzoic acid (PABA) and di-hydroxybenzoic acid at a final concen-
tration of 10 μg/L, as previously reported [29]. For growth at low osmolarity (9mM NaCl), low
salt LB broth and agar was used (Sigma). Sodium chloride was added to normal LB Broth and
agar to achieve 500mM NaCl.
Vi expression in Vi+ strains and its absence in Vi- strains was confirmed by slide agglutina-
tion and flow cytometry (S7 Fig) Vi+ S. Typhi (BRD948) and Vi+ S. Typhimurium (C5.507)
both expressed Vi, with expression lower in S. Typhimurium compared with S. Typhi. This is
consistent with previously reported differential Vi expression levels for these strains [14]. Nei-
ther the Vi- S. Typhi (BRD948 tviB-) nor Vi- S. Typhimurium strains (SGB1) expressed Vi.
Serum preparation
Blood was collected from ten healthy adults of mixed age, race and typhoid vaccination history
living in the UK (S1 Table) and left to clot at room temperature for 5 h. Three donors had pre-
viously received Vi CPS vaccine more than 3 years prior to serum collection. None had a his-
tory of suspected or confirmed Salmonella disease. Serum was then separated by centrifugation
and aliquots stored at -80°C. C6-deficient serum was from an individual with congenital C6
deficiency. When required, heat inactivation of serum was performed at 56°C for 2 hours
prior to use. Ethical approval for the use of blood and serum samples in this study was granted
by Life and Health Sciences Ethical Review Committee of the University of Birmingham.
Informed written consent was obtained from all participants. Anti-Salmonella IgG, IgA and
IgM antibody profiles against Vi and the O:4,5 (present on S. Typhimurium) and O:9 (present
on S. Enteritidis and S. Typhi) LPS-associated antigens were determined in the ten sera by
ELISA (S1 Fig). IgG to O:4,5 and O:9 LPS was present in 9/10 sera, while anti-Vi IgG was pres-
ent in 4/10 sera. IgM antibodies against all three antigens were detected in eight of the ten sera
and IgM anti-Vi antibodies in all sera.
Production of antibody-depleted human sera
Salmonella, at a concentration of 1 x 1011 CFU/ml, and fresh undiluted human sera were
cooled to 4°C. One part bacterial culture was added to nine parts human serum and the mix-
ture incubated on a rocker plate (20 rpm) at 4°C for 1 h. The sera were then centrifuged at
3,300 x g at 4°C for 5 minutes and aspirated into a new tube and the cycle repeated for three
incubations. Following the final adsorption, sera were filter-sterilized using a 0.2 μm filter and
frozen at -80°C until required.
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Anti-Salmonella antibody binding and complement deposition assay
Antibody binding to Salmonella was performed as previously described [19]. Briefly, 5 μl of
Salmonella in PBS/1% formaldehyde was added to 45μl 10% human serum or 45 μl 10% puri-
fied human antibodies in PBS (where 100% purified antibodies is equivalent to the concentra-
tion of antibodies in the corresponding whole serum) for antibody deposition assays. For
complement deposition, Salmonella were added to 45μl undiluted human serum or to 45 μl of
an antibody/complement mixture (25% antibody, 75% complement) (final bacterial concentra-
tion 1 x 109 CFU/ml). Antibody binding was detected using FITC-conjugated anti IgG, IgA or
IgM (Sigma) and complement binding detected using FITC-conjugated anti-C3 IgG or mouse
anti-C5-9 IgG followed by FITC-conjugated rabbit anti-mouse IgG (DAKO). Samples were
analyzed by flow cytometry using a FACSCalibur instrument (BD Biosciences) and Cell Quest
Pro software (BD Biosciences). Labeled Salmonella were identified based on their forward and
side scatter and the geometric mean fluorescence intensity (GMFI) in the FL1 channel recorded
as the relative antibody or complement binding level.
Characterization of Vi expression
Salmonella were grown to an OD600 of 0.5 in LB broth. Bacteria were washed twice and resus-
pended in PBS. Mouse anti-Vi antiserum from the Sclavo Behring Vaccines Institute of Global
Health (SBVGH, formerly Novartis Vaccines Institute of Global Health) was added to the Salmo-
nella at a final concentration of 1:800. Samples were incubated on ice for 1 hour followed by wash-
ing with PBS. Allophycocyanin-conjugated rabbit anti-mouse IgG (Sigma) was added at a final
concentration of 1:800 and samples incubated for 1 h, washed, and resuspended in PBS/1% form-
aldehyde. Samples were analyzed by flow cytometry using a FACSCanto instrument (BD Biosci-
ences) and FlowJo software (Tree Star, Inc). Salmonella were identified based on forward and side
scatter characteristics and the level of Vi expression determined as the GMFI in the FL4 channel.
Transmission Electron Microscopy (TEM)
Log phase Salmonella at a final concentration of 1 x 108 CFU/ml were exposed to fresh human
serum (Donor 1, S1 Table) or PBS for 10 minutes at 37°C. Following washing with PBS samples,
the bacteria were fixed for 20 minutes with a 1:1 ratio of 5% glutaraldehyde (GA), 1.4% ruthe-
nium hexamine trichloride (RHT) in 0.1M sodium cacodylate buffer (pH 7.42) and 100mM
L-Lysine monohydrochloride in PBS. A further fix of 40 minutes using 2.5% GA and 0.7% RHT
in sodium cacodylate buffer was applied. Following this, samples were washed in cacodylate
buffer and fixed with 1%Osmium tetroxide (Sigma), 0.05M Potassium ferrocyanide and 0.6%
RHT in 0.1M sodium cacodylate buffer for 30 minutes at RT. Cells were resuspended in 2% glu-
taraldehyde (TAAB Laboratories) and 4% paraformaldehyde (Sigma) in PBS for 1 hour at RT,
centrifuged at 10,000 rpm for 2 minutes and the supernatant replaced with 0.1M sodium cacody-
late and post fixed in 1% osmium tetroxide (TAAB Laboratories) in the same buffer at RT for 1 h.
Cells were then dehydrated in an ethanol series, with 1% uranyl acetate added at the 30% stage,
followed by propylene oxide and embedded in resin (TAAB Laboratories) prior to polymerization
at 60°C for 48 h. Sections were cut on a Leica Ultracut UC6 ultramicrotome at 70nm using a dia-
mond knife, contrasted with uranyl acetate and lead citrate and examined on an FEI Spirit Biot-
win 120kV transmission electron microscope and imaged with a Tietz F415 CCD camera.
Serum bactericidal assays with human sera
Killing of Salmonella with fresh, human serum was assessed as previously described [19]. 5 μl
Salmonella in log growth at a concentration of 1 x 107 CFU/ml was added to 45 μl human
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serum (final concentration 1 x 106 CFU/ml) and incubated at 37°C for 180 minutes on a rocker
plate at 20 rpm. At 45, 90 and 180 minutes, samples were taken and the concentration of viable
Salmonella was determined by serial dilution and plating on LB agar. Agar plates were incu-
bated overnight at 37°C and colonies counted the following day.
Blood cell killing assays
Killing of Salmonella by peripheral blood cells was based on the assay previously described
[30]. 1 x 107 CFU/ml Salmonella in log growth were opsonized at a 1:10 ratio with either 50%
human serum, which had been heat-inactivated for 2 hours at 56°C, and 50% fresh C6-defi-
cient serum or PBS at RT for 20 minutes. Such C6-deficient serum can act as source of opsoniz-
ing complement, but cannot promote C5b-9 membrane attack complex (MAC) formation.
Opsonized Salmonella were added to blood from healthy adult donors, which had been washed
twice with RPMI to remove endogenous antibody and complement, or to RPMI. Salmonella
were added at a 1:10 ratio to give a final concentration of 1x105 CFU/ml and incubated at 37°C
for 180 minutes. Samples were taken at 45, 90 and 180 minutes and the concentration of viable
bacteria assessed by serial dilution.
Serum bactericidal, and blood cell killing assays using purified human
antibodies
Serum bactericidal assays and blood cell killing assays using purified human antibodies against
the Vi and O:9 antigens of Salmonella were conducted as described above. Instead of serum,
11.25 μl anti-Vi and anti-O:9 antibodies (25% final volume) corresponding to 750 and 4268
IgG EU per ml respectively were combined, in a 1:4 dilution series, with 33.75 μl Salmonella-
antibody-depleted human serum (75% final volume).
Purification of human antibodies
Affinity purification of human antibodies was performed as previously described [31]. In brief,
sera from three healthy adults who had received the Vi CPS were pooled and passed through
affinity chromatography columns (HiTrap) containing either 2.5 mg Vi PS or 1 mg O:9 anti-
gen. Both purified polysaccharides were activated with adipic acid dihydrazide and linked to
N-hydroxysuccinamide-sepharose resins. Antibodies were sequentially eluted using 0.1 M gly-
cine pH 2.4 and 4MMgCl2 pH 7. Eluates were pooled and dialyzed overnight against PBS.
Purified antibodies were concentrated using Vivaspin columns (GE Healthcare) with a 10,000
MW cut-off.
ELISA for anti-Salmonella LPS O-antigen and anti-Vi antibodies
96-well flat-bottom plates (NUNCMaxisorp) were incubated overnight at 4°C with 100 μl per
well of 5 μg/ml TLR-grade smooth O:4,5 LPS or O:9 LPS (Alexis Biochemicals),1 μg/ml Vi
polysaccharide from SBVGH [32] or 1μg/ml outer membrane proteins (OMPs) produced from
S. Typhimurium SL3261. Plates were washed three times with PBS/0.05% Tween 20 and incu-
bated with 200 μl blocking buffer (PBS/1% BSA) per well at 37°C for 1 h. Plates were washed
again and incubated with a threefold dilution series of each sera in dilution buffer (PBS/1%
BSA/0.05% Tween 20) for 1 hour at 37°C. Plates were washed again and 100 μl of goat anti-
human alkaline phosphatase-labeled IgG, A or M (Southern Biotech) diluted 1:2000 in PBS
was added to each well and plates incubated for one hour at 37°C. Finally plates were washed
and 100 μl of substrate (Sigma N2770 p-Nitrophenyl phosphate) added to each well. Plates
were left to develop at 37°C for 1 h. The reciprocal of the dilution of sera giving an OD405 of 1
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was determined. This value was plotted as the anti-Salmonella LPS (O:4,5 or O:9) or anti-Vi
IgG, A or M, concentration.
Statistical Analysis
Data from experiments using different manipulations of Salmonella killing were compared
using Student’s t test. Comparisons of antibody binding and complement deposition on Salmo-
nella were performed using the Mann-Whitney U test.
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Supporting Information
S1 Fig. Anti-Salmonella antibody levels in sera from ten healthy adults. Levels of IgG (A),
IgA (B) and IgM (C) against the Salmonella antigens LPS O:4,5, LPS O:9 and Vi polysaccharide
as measured by ELISA. Lines represent median and interquartile range.
(TIF)
S2 Fig. Electron Microscopy scoring data. Damage to Salmonella Typhimurium (STM) and
S. Typhi (STY), expressing (Vi+) and not expressing Vi (Vi-) after exposure to human serum
was visualized by electron microscopy and quantified by scoring multiple images. The total
number of bacteria per frame was assessed (blue lines, right Y axis) and the number of dam-
aged Salmonella counted to give the percentage of damaged cells (red lines, left Y axis). Three
frames were counted. Data represent mean +/- SD.
(TIF)
S3 Fig. Background levels of fluorescence following sequential incubation of Salmonella
with PBS and secondary antibodies. The geometric mean fluorescence intensity was mea-
sured on the isogenic Vi-expressing and non-expressing S. Typhimurium (STM) and S. Typhi
(STY) strains following incubation with PBS and then FITC-conjugated anti-human IgG, IgM,
C3 and MAC. Values represent mean data from 3 separate experiments +/- SEM.
(TIF)
S4 Fig. Anti-Salmonella antibody titers before and following incubation with isogenic Vi+/-
S. Typhimurium and S. Typhi. Levels of IgG (A) or IgM (B) against the O:4,5, O:9 and Vi Sal-
monella antigens in serum from donor 1 (S1 Table) prior to, and following, incubation with
isogenic Vi-expressing or non-expressing S. Typhimurium (STM) or S. Typhi (STY) were mea-
sured by ELISA.
(TIF)
S5 Fig. Levels of anti-Vi, O:9, O:4,5 and OMP (STM) antibody in the purified antibody
pools. To assess the titer and presence of non-specific antibody, purified antibody preparations
and fresh serum (FS) were assessed for anti-Vi, O:9, O:4,5 and S. Typhimurium outer mem-
brane proteins (OMP) IgG titers by ELISA.
(TIF)
S6 Fig. Correlation between purified anti-Vi and anti-O:9 antibody binding. Levels of anti-
Vi and anti-O:9 binding to five wild-type S. Typhi isolates cultured at 9, 85 and 500mMNaCl
were plotted against each other to examine the relationship between the binding of the two
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antibodies to the Salmonella surface. Correlation was calculated using Spearman’s rank.
(TIF)
S7 Fig. Vi expression by isogenic Vi-expressing and -non-expressing Salmonella Typhi and
Typhimurium strains. Vi expression levels on isogenic pairs of Vi+/- S. Typhimurium (STM)
and S. Typhi (STY) were measured using flow cytometry. Representative image is shown.
(TIF)
S1 Table. Demographic data for human serum donors in study.Human serum donors used
in this study were of mixed age, sex and race. No donors had reported or confirmed previous
Salmonella infection. Three donors had received ViPS vaccine more than three years previous
to venesection.
(TIF)
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